The European Medicines Agency (EMA) has outlined its views on eSource direct capture of clinical trial data in response to questions from Novartis. EMA sees no theoretical obstacles to the use of the ...
The European Medicines Agency (EMA) has finalized its qualification opinion on Novartis’ eSource direct data capture technology. EMA reached its final position after running a public consultation that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results